ArticleBrain tumor pathology2026
Unveiling a genetic rarity: intracranial sarcomatous tumor with EWSR1::PATZ1 fusion-a case report and review of the literature.
Article in Brain tumor pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PATZ1 fusion neuroepithelial tumors (NET) are beginning to be recognized as a distinct molecular class of neoplasms that most often occur in children and young adults. These tumors are polyphenotypic, show diverse morphologic features, may be low- or high-grade, and tend to have an intermediate prognosis. We present a rare case of a high-grade NET harboring an EWSR1::PATZ1 fusion, identified through DNA methylation profiling and validated by gene expression analysis. The case involved a 21-year-old female presenting with headaches and seizures. The tumor was supratentorial in close relation to the lateral ventricle, preferentially located in the parietal lobe. Morphologically it showed predominant sarcomatous morphology with high mitotic activity and a high Ki-67 index leading to its initial diagnosis of gliosarcoma. Awareness of the emerging entity of PATZ1 fusion NET is important not only for accurate diagnostic and prognostic purposes but also for predicting response to therapy.
Indexed as
Identifiers
41565921What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.